Plasmapheresis Decreases Belatacept Exposure: Requires Consideration for Dose and Frequency Adjustments.

INTRODUCTION Belatacept was approved for kidney transplantation (KTx) in 2011. Belatacept has a long half life (9.8 d) with a small volume of distribution (0.09 L/k). After KTx, patients may require plasmapheresis (PP). However, the effects of PP on belatacept serum concentrations have not been reported. The aim of the present report is to examine the changes in serum concentration of belatacept with each PP in between belatacept dosing.